On August 28, 2025 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences (Press release, Halozyme, AUG 28, 2025, View Source [SID1234655561]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the Company’s participation are as follows:

Event:

2025 Wells Fargo Healthcare Conference

Format:

Fireside Chat and 1×1 Meetings

Presentation Date:

Thursday, September 4, 2025

Presentation Time:

10:30am PT / 1:30pm ET

Location:

Boston, MA

Event:

Morgan Stanley 23rd Annual Global Healthcare Conference

Format:

Fireside Chat and 1×1 Meetings

Date:

Monday, September 8, 2025

Presentation Time:

4:45am PT / 7:45am ET

Location:

New York, NY

Event:

H.C. Wainwright 27th Annual Global Investment Conference

Format:

1×1 Meetings

Date:

Tuesday, September 9, 2025

Location:

New York, NY

A live audio webcast of the presentations will be available in the Investor Relations section of the Company’s website. Replays of the audio webcasts will be available for 90 days following the conference.

On August 28, 2025 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings (Press release, Candel Therapeutics, AUG 28, 2025, View Source [SID1234655560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2025 Biopharma Back to School Conference (Boston, MA)
Date/Time: Wednesday, September 3, 2025, at 9:00 AM ET
Webcast Link: Citi / Candel Fireside Chat

Cantor Global Healthcare Conference (New York, NY)
Date/Time: Thursday, September 4, 2025, at 8:00 AM ET
Webcast Link: Cantor / Candel Fireside Chat

H.C. Wainwright 27th Annual Global Investment Conference (New York, NY)
Date/Time: Friday, September 5, 2025, at 7:00 AM ET
Webcast Link: H.C. Wainwright / Candel Presentation

Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.

On August 28, 2025 Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics, Triclonics and ADClonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET (Press release, Merus, AUG 28, 2025, View Source [SID1234655559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.

On August 28, 2025 Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) reported that management will participate in fireside chats at the following investor conferences in September (Press release, Kiniksa Pharmaceuticals, AUG 28, 2025, View Source [SID1234655558]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time
2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time

A live webcast of Kiniksa’s presentations will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the events will also be available on Kiniksa’s website within approximately 48 hours after the event.

On August 28, 2025 TG Therapeutics, Inc. (NASDAQ: TGTX) reported that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, reported it will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 – 5, 2025 (Press release, TG Therapeutics, AUG 28, 2025, View Source [SID1234655557]). The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source